Resmed Launches Sleep Institute to Advance Global Sleep Health Research and Insights

Resmed launches Sleep Institute to advance sleep health through global collaboration and evidence-based insights ahead of World Sleep Congress.

Quiver AI Summary

Resmed has launched the Sleep Institute, a global initiative aimed at enhancing the understanding and science of sleep health, partnering with healthcare professionals and policymakers to provide objective, evidence-based insights. This initiative comes just before the World Sleep Congress in Singapore, where it will address the significant issue of underdiagnosis of sleep disorders, particularly obstructive sleep apnea (OSA), affecting around 1 billion people globally. A recent survey highlighted a disconnect between the importance of sleep and its integration into healthcare discussions, underscoring the need for improved diagnostic pathways. The Sleep Institute aims to fill these gaps through research, expert perspectives, and collaboration to foster earlier diagnosis and create better policy strategies enhancing sleep health worldwide.

Potential Positives

Resmed launched the Sleep Institute, positioning itself as a leader in the global push to advance sleep health and address significant public health challenges related to sleep disorders.
The initiative will provide evidence-based insights and data to inform healthcare policies and clinical practices, potentially improving patient care and outcomes in sleep health.
The debut of the Sleep Institute at the World Sleep Congress enhances Resmed's visibility and credibility in a crucial healthcare sector, allowing for collaboration with global experts to tackle sleep disorder underdiagnosis.

Potential Negatives

While the launch of the Sleep Institute aims to address sleep health issues, the press release highlights a significant disconnect between the importance of sleep and the lack of healthcare provider engagement, as only one in three individuals reported being asked about their sleep by a doctor or nurse. This suggests potential shortcomings in the company’s current approach to addressing these important health challenges.
The focus on underdiagnosis of sleep disorders, particularly obstructive sleep apnea (OSA), may indicate that Resmed has not sufficiently addressed these gaps in their existing products and services, raising concerns about their effectiveness in the market.
The timing of the announcement, just before a major industry event, could be seen as an attempt to generate buzz rather than a genuine commitment to the issues presented, which may lead to skepticism among stakeholders about the company's motives.

FAQ

What is the Sleep Institute launched by Resmed?

The Sleep Institute is a global initiative focused on advancing sleep health through clinical insights and evidence-based research.

Why is addressing sleep disorders important?

Sleep disorders affect 1 billion people globally, leading to chronic health issues, lost productivity, and rising healthcare costs.

How does Sleep Institute support healthcare innovation?

It provides objective, non-commercial insights to inform care innovation, policy decisions, and elevate sleep health as a priority.

What issues will Sleep Institute address at World Sleep Congress?

They will discuss the underdiagnosis of obstructive sleep apnea (OSA) and solutions to improve access and treatment outcomes.

Where can I learn more about Sleep Institute's insights?

You can explore the latest insights and research at ResmedSleepInstitute.com or follow them on LinkedIn.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$RMD Congressional Stock Trading

Members of Congress have traded $RMD stock 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $RMD stock by members of Congress over the last 6 months:

REPRESENTATIVE KELLY MORRISON has traded it 5 times. They made 0 purchases and 5 sales worth up to $75,000 on 06/04, 04/28.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$RMD Insider Trading Activity

$RMD insiders have traded $RMD stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $RMD stock by insiders over the last 6 months:

MICHAEL J. FARRELL (Chief Executive Officer) has made 0 purchases and 6 sales selling 48,054 shares for an estimated $11,770,759.
BRETT SANDERCOCK (Chief Financial Officer) has made 0 purchases and 6 sales selling 13,527 shares for an estimated $3,424,598.
KAUSHIK GHOSHAL (Chief Commercial Officer, SaaS) sold 9,745 shares for an estimated $2,332,096
PETER C FARRELL has made 0 purchases and 5 sales selling 8,945 shares for an estimated $2,115,478.
JOHN HERNANDEZ sold 2,575 shares for an estimated $739,289
WITTE JAN DE sold 2,000 shares for an estimated $486,940
MICHAEL J RIDER (Global General Counsel) has made 0 purchases and 4 sales selling 221 shares for an estimated $55,314.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$RMD Hedge Fund Activity

We have seen 462 institutional investors add shares of $RMD stock to their portfolio, and 453 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MORGAN STANLEY removed 1,479,378 shares (-35.7%) from their portfolio in Q2 2025, for an estimated $381,679,524
GAMMA INVESTING LLC removed 729,713 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $188,265,954
NORGES BANK added 669,170 shares (+129.0%) to their portfolio in Q2 2025, for an estimated $172,645,860
OVERSEA-CHINESE BANKING CORP LTD removed 547,532 shares (-92.7%) from their portfolio in Q2 2025, for an estimated $141,263,256
MARSHALL WACE, LLP removed 543,857 shares (-97.7%) from their portfolio in Q2 2025, for an estimated $140,315,106
CONGRESS ASSET MANAGEMENT CO removed 484,773 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $125,071,434
CITADEL ADVISORS LLC added 328,864 shares (+853.5%) to their portfolio in Q2 2025, for an estimated $84,846,912

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$RMD Analyst Ratings

Wall Street analysts have issued reports on $RMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Mizuho issued a "Outperform" rating on 08/01/2025
RBC Capital issued a "Outperform" rating on 08/01/2025
UBS issued a "Buy" rating on 08/01/2025
JP Morgan issued a "Overweight" rating on 04/24/2025
Keybanc issued a "Overweight" rating on 04/24/2025

To track analyst ratings and price targets for $RMD, check out Quiver Quantitative's $RMD forecast page.

$RMD Price Targets

Multiple analysts have issued price targets for $RMD recently. We have seen 8 analysts offer price targets for $RMD in the last 6 months, with a median target of $290.0.

Here are some recent targets:

Adam Maeder from Piper Sandler set a target price of $270.0 on 08/01/2025
Jonathan Block from Stifel set a target price of $270.0 on 08/01/2025
Craig Wong-Pan from RBC Capital set a target price of $300.0 on 08/01/2025
Laura Sutcliffe from UBS set a target price of $325.0 on 08/01/2025
Anthony Petrone from Mizuho set a target price of $290.0 on 08/01/2025
Brett Fishbin from Keybanc set a target price of $298.0 on 08/01/2025
David Low from JP Morgan set a target price of $290.0 on 04/24/2025

Full Release

SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute , a global clinical insights initiative dedicated to advancing the science and understanding of sleep health.

Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions, and elevate sleep as a global health priority. The announcement comes ahead of the World Sleep Congress , taking place September 5–10 in Singapore.

Sleep disorders are among the most common health challenges worldwide, with an estimated 1 billion people living with obstructive sleep apnea (OSA) ¹ and about 852 million adults experiencing clinically relevant insomnia ² . Yet, the majority of people remain undiagnosed, fueling higher rates of chronic disease, lost productivity, and rising healthcare costs ³ . To help address this gap, Sleep Institute publishes original research, expert perspectives, and real-world data to support earlier and more accurate diagnosis and guide more informed clinical, policy, and system-level strategies.

“Sleep Institute reflects Resmed’s commitment to advancing sleep health worldwide,” said Kimberly L. Sterling, vice president, health research at Resmed, on behalf of Sleep Institute. “It’s about moving from awareness to action — giving global health and policy leaders the insights they need to close today’s care gaps and shape tomorrow’s sleep medicine.”

New findings from a U.S. consumer survey conducted by Sleep Institute ⁴ highlight this need. While more than four in five respondents said sleep is important to their overall health, only one in three reported that a doctor or nurse has asked them about their sleep in the past six months. This disconnect illustrates the need to better integrate sleep into routine healthcare and policy discussions, a central focus of Sleep Institute’s work.

Global Collaboration at World Sleep Congress

Sleep Institute will debut at the World Sleep Congress, with an expert led symposium tackling one of sleep medicine’s most pressing challenges: the global underdiagnosis of OSA. The session will examine barriers in diagnostic pathways for OSA and highlight scalable solutions to help improve access and outcomes.

The symposium, OSA Underdiagnosis – A world of difference, a common challenge , brings together clinical leaders from Iceland, Singapore, the United States, and Sweden, including:

Erna Sif Arnardóttir – director, Reykjavik University Sleep Institute; president, European Sleep Research Society (Iceland)
Chi-Hang Ronald Lee – professor of medicine, National University of Singapore; senior consultant, National University Heart Centre and Alexandra Hospital (Singapore)
Michelle R. Zeidler – professor of medicine, University of California, Los Angeles (UCLA); director, VA Greater Los Angeles Sleep Center (U.S.)
Ludger Grote – medical director, Sleep Disorders Center, Sahlgrenska University Hospital (Sweden)

“There is a clear and urgent need to close the diagnosis gap in sleep disorders such as OSA,” said Michelle R. Zeidler, MD, symposium panelist. “Sleep Institute’s focus on translating evidence into action will help clinicians, policymakers, and health systems take meaningful steps toward earlier detection and more personalized care.”

Through ongoing publications, data releases, and global collaborations, Sleep Institute aims to act as a catalyst for earlier diagnosis, stronger policies, and improved outcomes in sleep health worldwide. Learn more at ResmedSleepInstitute.com .

About Sleep Institute

Sleep Institute is a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Established by Resmed, Sleep Institute collaborates with researchers, clinicians, policymakers, and health system leaders to deliver objective, data-driven insights. Its goal is to help inform care model innovation, support policy development, and reinforce the vital role of sleep in improving health outcomes worldwide. Explore the latest insights at ResmedSleepInstitute.com and follow Sleep Institute on LinkedIn .

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.


For Media	For Investors

Julia Moser	Salli Schwartz
[email protected]	[email protected]
[email protected]	[email protected]

_________________________________

¹ Benjafield AV, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PMID: 31300334; PMCID: PMC7007763
² Benjafield AV, et al. Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis. Sleep Medicine Reviews.2025, https://doi.org/10.1016/j.smrv.2025.102121 .
³ American Academy of Sleep Medicine. Hidden Health Crisis: The Economic Burden of Undiagnosed Sleep Apnea. 2016. Available at:https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf
⁴ Methodology: A third-party provider surveyed 1,000 individuals in the U.S. All respondents were 18 or older, and the sample was census-balanced by age and gender. The third-party survey provider collected data through an online survey fielded from August 18 to 22, 2025. The survey respondents were independently sourced from Veridata Insights.